Cutaneous reactions post‐COVID‐19 vaccination. Case series and literature review
Abstract Background In Saudi Arabia, three approved vaccines against severe acute respiratory syndrome coronavirus 2 (AstraZeneca [AZD1222], Pfizer‐BioNTech [BNT162b2] and [Ad26. COV 2‐S] Moderna vaccine) have been administered to the population. Objective To characterise cutaneous adverse events as...
Main Authors: | Fatimah J. Al‐Muqarrab, Omar M. Alakloby, Mohammed A. Al Ameer, Abdulmohsen M. Alhajri |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-12-01
|
Series: | JEADV Clinical Practice |
Subjects: | |
Online Access: | https://doi.org/10.1002/jvc2.56 |
Similar Items
-
Local bullous reaction as a cutaneous reaction after mRNA‐boosted vaccination in a post‐COVID patient
by: Kwanhatai Kultawanich, et al.
Published: (2022-11-01) -
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature
by: Martora F, et al.
Published: (2022-11-01) -
Back to the Future: Can Vaccines Win the Long-Term Fight Against COVID-19?
by: Hildegund C. J. Ertl, et al.
Published: (2022-06-01) -
The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
by: Reese Jalal Ladak, et al.
Published: (2022-05-01) -
Transient dermatomyositis-like reaction following COVID-19 messenger RNA vaccination
by: Rodrigo A. Gutierrez, BS, et al.
Published: (2023-07-01)